L’assemblée générale des actionnaires du 24 avril 2026 a approuvé les comptes annuels relatifs à l’exercice social clôturé le 31 décembre 2025, en ce compris la distribution d’un dividende brut de € 1 ...
The general shareholders meeting of 24 April 2026 has approved the annual accounts as at 31 December 2025, including the distribution of a gross dividend of € 1.08 per share. The dividend will be paya ...
KFSH’s integrated framework connects medical genomics, an internationally accredited precision medicine laboratory, computational sciences, and translational research, creating a system where ...
Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial ...
Depressive disorders and MND both affect a significant portion of people living with HIV in the United States and worldwide, even when their HIV is successfully managed and treated with antiretroviral ...
Following completion of the Arrangement, Jushi expects the Nevada Common Stock will be listed for trading on the Canadian Securities Exchange and quoted on the OTCQX in place of the Subordinate Voting ...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today provided a corporate update on its ...
Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding in ...
About GT-02287 Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, ...
In celebration of DNA DAY™, A.D.A.M. Innovations Co. (Japanese corporate name Genesis Healthcare Co.) today announced a major update to GeneLife GeneAI Forecast, expanding the service to 15 AI-powered ...
A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence alone Of all MOUD, monthly ...
Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results